Asset Details
Do you wish to reserve the book?
Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
Do you wish to request the book?
Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
2020
Overview
Background
Malignant mesothelioma is an aggressive cancer and has a poor prognosis. Here, we analyzed the feasibility, molecular and gender aspects of targeted therapy recommendations for malignant mesothelioma based on the individual molecular tumor profile.
Methods
In this single‐center, real‐world retrospective analysis of our platform for precision medicine, we evaluated the molecular profiling of malignant mesothelioma in 14 patients, including nine men and five women. Tumor samples of the patients were examined with a 50 gene next‐generation sequencing (NGS) panel, immunohistochemistry, and fluorescence in situ hybridization, to detect possible molecular aberrations which may be targeted by off‐label therapy custom‐tailored to the individual patient.
Results
In total, we identified 11 mutations in six of the 14 patients, including BAP1, FANCA, NF1, NF2, PD‐L1, RAD52D, SETD2, SRC, and TP53. No mutation was detected in eight of the 14 patients. Targeted therapy was recommended for 11 out of the 14 patients. All recommendations were mainly based on the molecular characteristics determined by immunohistochemistry. Targeted therapy recommendations were significantly more often for men than women due to gender‐specific differences in PDGFRα expression. Eventually, four patients received the targeted therapy, of whom one patient subsequently achieved stable disease.
Conclusions
Our observations suggest that a molecular‐guided treatment approach is feasible for the management of advanced malignant mesothelioma. Our analysis revealed gender specific differences in PDGFRα expression that should be further evaluated in clinical trials.
Publisher
John Wiley & Sons Australia, Ltd,John Wiley & Sons, Inc,Wiley
Subject
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biomarkers, Tumor - genetics
/ Cloning
/ DNA
/ Female
/ Gene Expression Regulation, Neoplastic
/ High-Throughput Nucleotide Sequencing
/ Humans
/ Lymphoma
/ Male
/ Mesothelioma, Malignant - drug therapy
/ Mesothelioma, Malignant - genetics
/ Mesothelioma, Malignant - pathology
/ Mutation
/ Neoplasm Recurrence, Local - drug therapy
/ Neoplasm Recurrence, Local - genetics
/ Neoplasm Recurrence, Local - pathology
/ Original
/ Patients
/ Peritoneal Neoplasms - drug therapy
/ Peritoneal Neoplasms - genetics
/ Peritoneal Neoplasms - secondary
/ Tumors
